Tearsheet

Hinge Health (HNGE)


Market Price (4/22/2026): $45.0 | Market Cap: $3.6 Bil
Sector: Health Care | Industry: Health Care Technology

Hinge Health (HNGE)


Market Price (4/22/2026): $45.0
Market Cap: $3.6 Bil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51%

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.

Weak multi-year price returns
2Y Excs Rtn is -21%, 3Y Excs Rtn is -52%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -546 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -93%

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 109%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19%

Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -10%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 51%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28%
3 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Remote Patient Monitoring, and Wearable Health Devices.
4 Weak multi-year price returns
2Y Excs Rtn is -21%, 3Y Excs Rtn is -52%
5 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -546 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -93%
6 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 109%
7 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -19%
8 Key risks
HNGE key risks include [1] intense competition and market commoditization threatening its premium pricing position and technological advantages, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Hinge Health (HNGE) stock has lost about 5% since 12/31/2025 because of the following key factors:

1. Analyst Price Target Reductions Reflecting Tempered Expectations.

Despite reporting strong Q4 2025 financial results, several analysts revised down their price targets for Hinge Health, signaling a more cautious outlook on the stock's near-term potential. For example, Evercore ISI trimmed its price target on Hinge Health to $45 from $50, while maintaining an Outperform rating. Similarly, Canaccord Genuity Group cut its target price from $65.00 to $53.00. These reductions indicate a reassessment of the company's valuation or growth trajectory by market experts.

2. Significant Insider Selling by a Key Executive.

A substantial insider sale by Chairman Gabriel M.I. Mecklenburg in March 2026 may have contributed to negative sentiment. On March 6, 2026, Mecklenburg sold 166,666 shares, a transaction valued at approximately $7.69 million based on the closing price of $46.14 on that day. Such a large sale by a top executive can be interpreted by investors as a lack of strong confidence in the company's future stock performance, often leading to downward pressure.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -4.1% change in HNGE stock from 12/31/2025 to 4/21/2026 was primarily driven by a -32.6% change in the company's P/S Multiple.
(LTM values as of)123120254212026Change
Stock Price ($)46.4544.56-4.1%
Change Contribution By: 
Total Revenues ($ Mil)35558865.7%
P/S Multiple9.06.0-32.6%
Shares Outstanding (Mil)6980-14.1%
Cumulative Contribution-4.1%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/21/2026
ReturnCorrelation
HNGE-4.1% 
Market (SPY)-5.4%18.9%
Sector (XLV)-5.7%9.7%

Fundamental Drivers

The -9.2% change in HNGE stock from 9/30/2025 to 4/21/2026 was primarily driven by a -39.7% change in the company's P/S Multiple.
(LTM values as of)93020254212026Change
Stock Price ($)49.0844.56-9.2%
Change Contribution By: 
Total Revenues ($ Mil)33558875.3%
P/S Multiple10.06.0-39.7%
Shares Outstanding (Mil)6980-14.1%
Cumulative Contribution-9.2%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/21/2026
ReturnCorrelation
HNGE-9.2% 
Market (SPY)-2.9%16.4%
Sector (XLV)5.3%4.3%

Fundamental Drivers

null
null

Market Drivers

3/31/2025 to 4/21/2026
ReturnCorrelation
HNGE  
Market (SPY)16.3%21.9%
Sector (XLV)1.3%2.2%

Fundamental Drivers

null
null

Market Drivers

3/31/2023 to 4/21/2026
ReturnCorrelation
HNGE  
Market (SPY)63.3%21.9%
Sector (XLV)18.0%2.2%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
HNGE Return----24%-5%17%
Peers Return-46%-65%-39%-63%-28%-4%-97%
S&P 500 Return27%-19%24%23%16%4%89%

Monthly Win Rates [3]
HNGE Win Rate----50%50% 
Peers Win Rate31%25%44%33%28%42% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
HNGE Max Drawdown-----7%-33% 
Peers Max Drawdown-53%-68%-59%-71%-58%-31% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, AMWL, DRIO.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/21/2026 (YTD)

How Low Can It Go

HNGE has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

Unique KeyEventXLVS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-16.1%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven19.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven599 days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-28.8%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven40.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven116 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-15.8%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven18.8%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven326 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-40.6%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven68.3%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,100 days1,480 days

Compare to TDOC, AMWL, DRIO

In The Past

SPDR Select Sector Fund's stock fell -16.1% during the 2022 Inflation Shock from a high on 4/8/2022. A -16.1% loss requires a 19.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Hinge Health (HNGE)

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients. We have designed our platform to address a broad spectrum of MSK care—from acute injury, to chronic pain, to post-surgical rehabilitation. Members receive personalized and largely automated MSK care through our AI-powered motion tracking technology and a proprietary electrical nerve stimulation wearable device, all designed and monitored by our AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Our platform can improve pain and function and reduce the need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere and embrace movement as a way of life. There is no shortage of new technologies in the healthcare industry, yet the cost of care continues to rise. In other industries, the launch of new technologies has generally improved end-user experiences and lowered costs. In healthcare, however, new technologies have not always been successful in lowering the cost of care or improving clinical outcomes. We believe there are two key reasons for healthcare’s idiosyncratic response to technology: • Automating most aspects of care is difficult because so many healthcare interventions involve unstructured physical tasks. • The current framework for healthcare reimbursement has specific pathways to pay for care, which means new technologies are constrained to deliver within this framework. At Hinge Health, we have taken these challenges head-on. To address the automation of care, we have weaved together AI-enabled capabilities - such as our AI-powered motion tracking technology, TrueMotion, our proprietary FDA-cleared wearable device, Enso, and our AI-supported care team - to deliver scalable and personalized MSK care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. We have done this while improving our high member satisfaction over time. To address healthcare reimbursement constraints, we developed novel billing methods for our innovative technology by both directly selling to employers while also partnering with health plans, pharmacy benefit managers (“PBMs”), third-party administrators (“TPAs”), and other ecosystem entities to efficiently provide our platform to clients and members. While the MSK market is massive, existing solutions have fallen short as they are often expensive, ineffective, inconvenient to access, and delivered in a one-to-one or few-to-one care setting. Effective MSK care should be engaging, easy to use, and accessible anytime, anywhere. We developed Hinge Health to be simple and accessible, complete, personalized, and scalable. • Simple and accessible: We provide members access to our platform at no direct cost to them and without a copay or deductible. Members can access our broad spectrum of MSK care through a single on-demand app, designed to provide an engaging, seamless, and convenient digital experience whenever and wherever the member chooses. Potential members can complete a simple intake form, download the app, and start exercises soon thereafter. During the year ended December 31, 2024, approximately 64% of members were onboarded on the same day they completed their intake form, and approximately 75% of members were onboarded within the first week. • Complete: Our platform offers a wide range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. We also offer non-addictive and non-invasive pain relief via electrostimulation through our proprietary FDA-cleared wearable device, Enso, that is seamlessly integrated into our platform. • Personalized: Our platform delivers smarter care through AI and machine learning. Our AI model is trained on a large, proprietary MSK data set, and our technology is continuously learning and improving as each new member enrolls and engages with our programs, which creates a positive feedback loop. As of March 31, 2025, we had treated over one million members and our programs had tracked over 74 million activity sessions and 32 million member-reported outcome logs. We focus on personalization to keep members moving: from customized care plans to real-time in-app exercise feedback based on the member’s input and our proprietary motion tracking technology. • Scalable: Our AI-powered motion tracking technology, TrueMotion, allows us to deliver scalable and largely automated care. According to our estimates based on data from 2024, our platform reduced the number of human care team hours associated with traditional physical therapy by approximately 95%. While most of our programs provide members with access to a dedicated care team, our technology automates most aspects of care delivery while allowing our members to progress through their exercise therapy sessions on their own time. We have developed an efficient go-to-market model by working directly with our partners and clients. We seek to be the best solution on the market, the most validated solution on the market, and the easiest to buy. Our clients are primarily self-insured employers and include many of the nation’s leading enterprises across a broad range of industries and sizes. Within this segment, we also serve many public sector self-insured employers, such as state and local city governments and labor unions. In most instances, we partner with clients’ health plans, TPAs, PBMs, or other ecosystem entities to reduce the friction of contracting, procurement, security and IT reviews, onboarding, and billing. We are also in the early stages of expanding to serve health plans’ fully-insured and Medicare Advantage populations and federal insurance plans. As of December 31, 2024, we had approximately 20 million contracted lives across more than 2,250 clients. We had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies, as of December 31, 2024. Despite this progress, our current contracted lives only represent 5% of our total addressable market. We believe that we grow efficiently because of our scalable, repeatable go-to-market model. We sell through our direct sales force and our partners. Once we contract with a client, we are most often the sole digital MSK care provider offered to their contracted lives. Our average contract term is three years. For the term of each contract, we are able to enroll, engage, and re-engage the client’s eligible lives, driving a recurring, repeatable revenue model, which is demonstrated in our net dollar retention of 117% as of December 31, 2024. Our 12-month client retention rate was 98% as of December 31, 2024. Additionally, we have a high level of client satisfaction, as shown by our client net promoter score (“NPS”) of 87 as of October 31, 2024. We also invested early in building our partner network. As of March 31, 2025, we had over 50 partners. Our partners include the five largest national health plans by self-insured lives, and the top three PBMs by market share. As of that date, we had retained 100% of our partners that we chose to work with since inception, excluding partners who were acquired. We have experienced significant growth since our inception, with a recurring revenue business model. As of December 31, 2024, we had over 532,000 members and more than 2,250 clients, compared to approximately 371,000 members and approximately 1,650 clients as of December 31, 2023. Our principal executive offices are located in San Francisco, California.

AI Analysis | Feedback

Livongo for musculoskeletal health

Peloton for medical physical therapy

AI Analysis | Feedback

  • Digital Musculoskeletal (MSK) Care Service: A comprehensive, AI-powered virtual program that provides personalized and largely automated care for joint and muscle health, spanning prevention, acute injury, chronic pain, and post-surgical rehabilitation.
  • TrueMotion AI-powered Motion Tracking Technology: An integrated technology within their service that utilizes AI for real-time exercise feedback and tracks member progress, enabling scalable and personalized therapy.
  • Enso Electrical Nerve Stimulation Wearable Device: A proprietary, FDA-cleared wearable device seamlessly integrated into the service, delivering non-addictive and non-invasive pain relief via electrostimulation.

AI Analysis | Feedback

Hinge Health (HNGE) primarily sells to other companies.

The company's major customers are:

  • Self-insured employers, including many of the nation’s leading enterprises across a broad range of industries and sizes. As of December 31, 2024, Hinge Health had active client agreements with 49% of the Fortune 100 companies and 42% of the Fortune 500 companies.
  • Public sector self-insured employers, such as state and local city governments and labor unions.

While Hinge Health partners with major national health plans and PBMs to facilitate access to clients, and is expanding to serve health plans' fully-insured and Medicare Advantage populations directly, its primary clients are explicitly stated as self-insured employers.

The provided text does not list specific names of the Fortune 100, Fortune 500, or other employer clients. Therefore, specific customer company names and their symbols cannot be provided.

AI Analysis | Feedback

null

AI Analysis | Feedback

Daniel Perez, Co-Founder and Chief Executive Officer

Daniel Perez co-founded Hinge Health in 2014. He holds a B.S. in Biology from Westminster University and completed a DPhil (PhD) in Biochemistry from the University of Oxford. Prior to Hinge Health, he co-founded Marblar and the Oxbridge Biotech Roundtable. He was inspired to start Hinge Health with Gabriel Mecklenburg due to their personal experiences with musculoskeletal injuries.

James Budge, Chief Financial Officer

James Budge joined Hinge Health as Chief Financial Officer in March 2023. He brings 25 years of CFO experience across various public and private high-growth technology companies. His previous CFO roles include Automation Anywhere, Pluralsight, Anaplan, Genesys Cloud Services, and Rovi Corporation. Budge has a track record of raising capital, taking companies public, and overseeing numerous acquisitions. He holds a B.S. in Accounting from Brigham Young University. His career has involved accelerating growth for public and late-stage private companies.

Gabriel Mecklenburg, Co-Founder and Executive Chairman

Gabriel Mecklenburg is the Co-Founder and Executive Chairman of Hinge Health, having also served as Chief Operating Officer from October 2014 to February 2021. He co-founded Marblar and Oxbridge Biotech Roundtable Ltd. He holds an M.Sc. in Materials Science from the University of Cambridge and an M. Phil. in Bioengineering from Imperial College London.

Jim Pursley, President

Jim Pursley has served as President of Hinge Health since March 2021. Before joining Hinge Health, he was the Chief Commercial Officer of Livongo Health. He also held various executive positions at Care Innovations and GE HealthCare Technologies. He earned an M.B.A. from Kellogg School of Management at Northwestern University and a B.S. in Management Science and Information Systems from Pennsylvania State University.

Dr. Jeff Krauss, Chief Medical Officer

Dr. Jeff Krauss is the Chief Medical Officer at Hinge Health, a role he assumed in September 2018.

AI Analysis | Feedback

The key risks to Hinge Health's business include:

  1. Challenges with Healthcare Reimbursement and Regulatory Environment: Hinge Health's business model relies on developing "novel billing methods" and partnering with various entities like health plans and pharmacy benefit managers (PBMs) to navigate the complex healthcare reimbursement framework. The healthcare industry is heavily regulated, and any changes to reimbursement policies, challenges in gaining acceptance for their billing methods, or difficulties in expanding into new, highly regulated segments like fully-insured and Medicare Advantage populations and federal insurance plans, could significantly impact their revenue and growth trajectory.
  2. Dependence on AI-Powered Technology Efficacy and Member Engagement: Hinge Health's core value proposition is built on its AI-powered motion tracking technology (TrueMotion) and proprietary FDA-cleared wearable device (Enso), which largely automate care for joint and muscle health and aim to reduce human care team hours by approximately 95%. A significant risk lies in the continuous efficacy of these technologies in delivering superior clinical outcomes, maintaining high member satisfaction, and sustaining member engagement, particularly given the inherent difficulty of automating unstructured physical tasks in healthcare. Any technical failures, lack of desired clinical results, or a decline in member trust and adoption could undermine the company's value proposition.
  3. Intense Competition and Market Penetration Challenges: While Hinge Health operates in a "massive" musculoskeletal (MSK) market, the healthcare industry has "no shortage of new technologies," implying a highly competitive landscape. Despite significant client retention rates and contracts with a large percentage of Fortune 100 and 500 companies, Hinge Health's current contracted lives represent only 5% of its total addressable market. The company faces the ongoing challenge of effectively competing with existing solutions and new market entrants, and efficiently penetrating the remaining 95% of the market to sustain its growth.

AI Analysis | Feedback

null

AI Analysis | Feedback

The addressable market for Hinge Health's main products and services, which include its digital musculoskeletal (MSK) care platform, is approximately 400 million lives in the U.S.

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Hinge Health (HNGE)

Hinge Health anticipates several key drivers for its revenue growth over the next 2-3 years, primarily stemming from its extensive market opportunity, strategic partnerships, and expansion into new customer segments.
  1. Growth in contracted lives and client acquisition: Hinge Health currently serves approximately 20 million contracted lives, which represents only 5% of its total addressable market. This leaves substantial room for growth through acquiring new self-insured employers and increasing penetration within the Fortune 100 and Fortune 500 companies, where it already has significant presence but still opportunities to expand.
  2. Expansion into new market segments: The company is in the early stages of broadening its reach beyond self-insured employers to serve fully-insured and Medicare Advantage populations of health plans, as well as federal insurance plans. This strategic expansion into new payer types opens up large, previously untapped revenue streams.
  3. Deepening engagement and penetration within existing client base: Hinge Health benefits from a recurring revenue model, demonstrated by a net dollar retention of 117% as of December 31, 2024, and a 12-month client retention rate of 98%. This indicates a strong ability to enroll, engage, and re-engage eligible members within its existing client contracts, leading to organic revenue growth over the typical three-year contract term.
  4. Leveraging and expanding its partner network: With over 50 partners, including the five largest national health plans and top three PBMs, Hinge Health's partner network is a crucial component of its efficient go-to-market strategy. These partnerships reduce friction in contracting, procurement, and onboarding, facilitating the efficient provision of its platform to clients and members, thereby accelerating client acquisition and growth in contracted lives.

AI Analysis | Feedback

null

Trade Ideas

Select ideas related to HNGE.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03312026PGNYProgynyDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
0.0%0.0%0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03272026CNCCenteneDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
2.3%2.3%-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG03272026OSCROscar HealthDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap
3.0%3.0%-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper03202026WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
-0.4%-0.4%-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%03202026GILDGilead SciencesQualityQ | Momentum | UpsideQuality Stocks with Momentum and Upside
Buying quality stocks with strong momentum but still having room to run
1.6%1.6%-2.2%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Price44.566.006.317.286.79
Mkt Cap3.61.10.10.00.6
Rev LTM5882,53024922419
Op Inc LTM-546-163-105-37-134
FCF LTM165137-66-2656
FCF 3Y Avg-167-124-32-32
CFO LTM171294-66-2673
CFO 3Y Avg-313-114-32-32

Growth & Margins

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Rev Chg LTM50.6%-1.5%-2.0%-17.3%-1.8%
Rev Chg 3Y Avg-1.8%-3.4%-3.6%-3.4%
Rev Chg Q45.6%0.3%-22.1%-31.2%-10.9%
QoQ Delta Rev Chg LTM10.0%0.1%-5.9%-9.6%-2.9%
Op Inc Chg LTM-1,612.2%21.7%51.6%36.5%29.1%
Op Inc Chg 3Y Avg-10.0%24.6%11.6%11.6%
Op Mgn LTM-92.9%-6.5%-42.2%-163.9%-67.6%
Op Mgn 3Y Avg-48.6%-7.6%-75.5%-217.9%-62.0%
QoQ Delta Op Mgn LTM10.5%0.6%4.1%-3.2%2.4%
CFO/Rev LTM29.2%11.6%-26.5%-116.0%-7.4%
CFO/Rev 3Y Avg-12.2%-44.6%-136.0%-44.6%
FCF/Rev LTM28.1%5.4%-26.5%-116.7%-10.5%
FCF/Rev 3Y Avg-6.5%-48.6%-137.3%-48.6%

Valuation

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
Mkt Cap3.61.10.10.00.6
P/S6.00.40.42.21.3
P/Op Inc-6.5-6.5-1.0-1.3-3.9
P/EBIT-6.5-4.9-1.0-1.4-3.2
P/E-6.7-5.3-1.1-1.2-3.3
P/CFO20.73.6-1.6-1.91.0
Total Yield-14.9%-18.8%-92.5%-84.8%-51.8%
Dividend Yield0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-9.1%-82.6%-1,281.5%-82.6%
D/E0.01.00.00.60.3
Net D/E-0.10.2-1.70.10.0

Returns

HNGETDOCAMWLDRIOMedian
NameHinge He.Teladoc .American.DarioHea. 
1M Rtn4.9%12.1%10.1%-8.9%7.5%
3M Rtn7.1%-1.2%37.2%-41.5%3.0%
6M Rtn-10.4%-30.7%12.7%-49.5%-20.6%
12M Rtn18.6%-7.8%-11.9%-50.2%-9.9%
3Y Rtn18.6%-78.4%-85.1%-89.8%-81.8%
1M Excs Rtn-3.7%3.6%1.6%-17.5%-1.1%
3M Excs Rtn3.1%-5.1%33.2%-45.4%-1.0%
6M Excs Rtn-15.6%-35.7%9.8%-50.2%-25.6%
12M Excs Rtn-15.1%-45.9%-43.3%-85.2%-44.6%
3Y Excs Rtn-52.1%-147.3%-155.5%-160.9%-151.4%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024
Single Segment390293
Total390293


Net Income by Segment
$ Mil20252024
Single Segment-12-108
Total-12-108


Price Behavior

Price Behavior
Market Price$44.56 
Market Cap ($ Bil)3.6 
First Trading Date05/22/2025 
Distance from 52W High-26.4% 
   50 Days200 Days
DMA Price$41.06$41.06
DMA Trendindeterminatedown
Distance from DMA8.5%8.5%
 3M1YR
Volatility64.0%65.3%
Downside Capture0.050.69
Upside Capture67.28149.36
Correlation (SPY)14.8% 
HNGE Betas & Captures as of 3/31/2026

 1M2M3M6M1Y3Y
Beta0.310.790.870.730.350.30
Up Beta-5.88-2.47-1.69-0.27-0.04-0.65
Down Beta0.633.201.580.32-0.36-0.55
Up Capture62%114%81%87%106%13%
Bmk +ve Days7162765139424
Stock +ve Days10223161102102
Down Capture86%8%127%129%110%68%
Bmk -ve Days12233358110323
Stock -ve Days12203265108108

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE23.0%65.4%0.61-
Sector ETF (XLV)9.2%16.0%0.371.8%
Equity (SPY)23.7%12.7%1.5221.6%
Gold (GLD)41.4%27.5%1.25-0.4%
Commodities (DBC)22.4%16.2%1.25-3.3%
Real Estate (VNQ)14.2%13.8%0.7211.0%
Bitcoin (BTCUSD)-10.4%42.7%-0.1411.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE4.2%65.4%0.61-
Sector ETF (XLV)5.9%14.6%0.221.8%
Equity (SPY)10.8%17.1%0.4921.6%
Gold (GLD)21.6%17.8%0.99-0.4%
Commodities (DBC)10.9%18.8%0.47-3.3%
Real Estate (VNQ)4.1%18.8%0.1211.0%
Bitcoin (BTCUSD)3.8%56.4%0.2911.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with HNGE
HNGE2.1%65.4%0.61-
Sector ETF (XLV)9.5%16.5%0.471.8%
Equity (SPY)13.9%17.9%0.6721.6%
Gold (GLD)13.7%15.9%0.71-0.4%
Commodities (DBC)8.2%17.6%0.39-3.3%
Real Estate (VNQ)5.4%20.7%0.2311.0%
Bitcoin (BTCUSD)68.0%66.9%1.0711.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date3312026
Short Interest: Shares Quantity4.2 Mil
Short Interest: % Change Since 31520266.0%
Average Daily Volume0.9 Mil
Days-to-Cover Short Interest4.8 days
Basic Shares Quantity79.8 Mil
Short % of Basic Shares5.3%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
2/10/202617.3%22.7%34.5%
11/4/2025-15.1%-17.1%-6.4%
8/5/202525.6%16.1%16.2%
SUMMARY STATS   
# Positive222
# Negative111
Median Positive21.4%19.4%25.3%
Median Negative-15.1%-17.1%-6.4%
Max Positive25.6%22.7%34.5%
Max Negative-15.1%-17.1%-6.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
12/31/202503/03/202610-K
09/30/202511/07/202510-Q
06/30/202508/11/202510-Q
03/31/202505/23/2025424B4

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/10/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q1 2026 Revenue171.00 Mil172.00 Mil173.00 Mil10.3% Higher NewGuidance: 156.00 Mil for Q4 2025
Q1 2026 Non-GAAP Income from Operations30.00 Mil31.00 Mil32.00 Mil-11.4% Lower NewGuidance: 35.00 Mil for Q4 2025
Q1 2026 Non-GAAP Operating Margin 18.0%    
2026 Revenue732.00 Mil737.00 Mil742.00 Mil28.6% Higher NewGuidance: 573.00 Mil for 2025
2026 Non-GAAP Income from Operations151.00 Mil153.50 Mil156.00 Mil43.5% Higher NewGuidance: 107.00 Mil for 2025
2026 Non-GAAP Operating Margin 21.0%    

Prior: Q3 2025 Earnings Reported 11/4/2025

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
Q4 2025 Revenue155.00 Mil156.00 Mil157.00 Mil   
Q4 2025 Non-GAAP Income from Operations34.00 Mil35.00 Mil36.00 Mil   
2025 Revenue572.00 Mil573.00 Mil574.00 Mil4.2% RaisedGuidance: 550.00 Mil for 2025
2025 Non-GAAP Income from Operations106.00 Mil107.00 Mil108.00 Mil33.8% RaisedGuidance: 80.00 Mil for 2025

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Perez, Daniel AntonioCEO & Co-FounderDirectSell106202646.38166,665  Form
2Pursley, JamesPresidentDirectSell1223202548.4015,000725,95037,254,715Form
3Budge, JamesChief Financial OfficerDirectSell1223202548.4110,491507,83721,355,866Form
4Perez, Daniel AntonioCEO & Co-FounderDirectSell1216202548.53166,670  Form
5Robinson, Elliott See footnoteSell120920250.000  Form